Dataset from A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)

This is a study in adults who are in hospital for acute heart failure. The purpose of this
study is to find out whether starting to take a medicine called empagliflozin soon after
first being treated in hospital helps people with acute heart failure.

Participants are in the study for about 3 months. At the beginning, participants are still in
hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are
put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group
takes

1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain
any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is
used to treat type 2 diabetes.

During the study, the doctors check whether participants have additional heart failure events
like needing to go to the hospital again because of heart failure. The participants answer
questions about how their heart failure affects their life. We then compare the results
between the empagliflozin and placebo groups. The doctors also regularly check the general
health of the participants.